Advanced searches left 3/3

Alzheimer's Disease - Crossref

Summarized by Plex Scholar
Last Updated: 14 April 2022

* If you want to update the article please login/register

Robust Discovery of Mild Cognitive Impairment Subtypes and Their Risk of Alzheimer's Disease Conversion Using Unsupervised Machine Learning and Gaussian Mixture Modeling

Providers with the ability to accurately predict Alzheimer's disease in its early stages can help physicians make more informed clinical decisions on therapy decisions. The aim of this review was to see if unsupervised discovery of Mild Cognitive Impairment's latent classes of participants could be useful in determining different prodromal AD stages and/or AD conversion risk among subjects with a low MCI to AD conversion risk. Methods: The MCI-to-AD conversion process yielded the identification of 681 patients with early MCI. MCI subjects were found three distinct clusters among MCI subjects by consensus clustering. Hence, prodromal AD participants were present in just two clusters. Conclusion: We successfully identified three new latent classes in MCI subjects with varying dangers of MCI-to-AD conversion through consensus clustering. Two of the found classes may have two different prodromal manifestations of Alzheimer's disease.

Source link: https://doi.org/10.2174/1567205018666210831145825


A new diagnostic approach in Alzheimer's disease: The critical flicker fusion threshold

Alzheimer's disease is the most common cause of dementia in seniors. In this research, we intended to use the critical flicker fusion threshold test to diagnose AD in the early stage. The mean CFF value of the AD group was significantly lower than the control group, according to a study. Also, there was also a positive correlation between CFF value and MMSE score, as shown by the chart. Twenty-four patients were in the early-stage AD group, and 24 patients were in the middle-stage AD group. When we compared the patients in early- and middle-stage AD and control groups, we noticed a significant difference in CFF values between the three groups. Conclusions: Between AD and healthy groups, there is a significant difference in mean CFF values. CFF testing may be helpful in determining AD in the early stages.

Source link: https://doi.org/10.1590/1980-5764-dn-2021-0054


Cortisol Reactivity to a physical stressor in Patients with Depression and Alzheimer's disease

However, there is no evidence indicating cortisol activity after a physical stressor in patients with AD and MDD. This research sought to determine the cortisol reactivity to a single session of physical activity in patients with MDD and AD, as well as healthy control older adults. Methods: During 30 minutes of moderate intensity, HC individuals and elderly with clinical diagnosis of MDD and AD were pushed to a single bout of aerobic exercise in a treadmill. ANOVA with repeated measures showed no interaction for cortisol on the time [F=1. 285; p=0. 293] and no effect for group despite the group's age. Patients with MDD were small, and they were trivial for patients with AD and HC groups. Conclusions: Both participants showed a reduced cortisol response to a physical stressor, which can be attributed to an impairment in dealing with an acute stressor.

Source link: https://doi.org/10.1590/1980-5764-dn-2021-0066


Medication reconciliation role and value in Alzheimer's disease treatment

Object: To investigate the role and value of medication reconciliation in AD treatment. Methods: 100 patients over the age of 65 with AD were randomly divided into two groups: conventional therapy and drug reforming. Results: Following the intervention, the medications and amounts of medications in the MED group were less compared to the CON group, as well as a reduced medication error rate. Patients in the MED group were more likely to be well-nourished than those in the CON group, according to Mini-mental state examination results and the percentage of well-nourished patients. When compared to the CON group, it was also found that the physical fitness competence test and the percentage of patients with abnormal swallowing were lower. In the MED group, the risk of adverse drug reactions was less than in the CON group. Conclusion: Medication reconciliation can eliminate AD patients' medication deviations from prescription.

Source link: https://doi.org/10.1590/0004-282x-anp-2021-0147


Is the Alzheimer's Disease Assessment Scale-Cognitive Subscale useful in screening for mild cognitive impairment and Alzheimer's disease? A systematic review

Background: Mild cognitive impairment and Alzheimer's disease screening is used to determine whether cognitive decline in older adults is due to pathological rather than normal aging. Objective: This report was designed to determine the diagnostic results of the Alzheimer's Disease Assessment Scale-Cognitive Subscale in MCI and AD screening. The sROC AUC was 0. 97 % and 0. 93 respectively in 2,517 AD patients from ten studies, the pooled sensitivity and pooled specificity were 0. 91 and 0. 93 respectively, with an overall sensitivity and pooled specificity of 0. 91 and 0. 93 respectively. Conclusion: The ADAS-Cog is a screening tool for both MCI and AD, but has improved diagnostic results in patients with AD. ADAS-Cog is a first-stage screener that can be used right away if early screening for AD is needed.

Source link: https://doi.org/10.2174/1567205019666220404104854

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions